Anna Angona

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

Alberto Álvarez‐Larrán, Arturo Pereira, Francisco Cervantes et al. · Blood · 2011 · 221 citations · Full text

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 164 citations

Hematological Malignancy, Bone Marrow Failure, Momelotinib Versus Danazol +6

Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia

Juan Carlos Hernández‐Boluda, Alberto Álvarez‐Larrán, Montse Gómez et al. · British Journal of Haematology · 2010 · 89 citations · Full text

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Tiziano Barbui, Arianna Ghirardi, Arianna Masciulli et al. · Leukemia · 2019 · 87 citations · Full text

Hematological Malignancy, Medicine, Pathology +6

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Tiziano Barbui, Alessandro M. Vannucchi, Alberto Álvarez‐Larrán et al. · Leukemia · 2021 · 80 citations · Full text